Clinical Trials Sponsored by ImevaX

Total 43 results

ImevaX

Completed

Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers (IMX-02)

Helicobacter Pylori Infected Subjects | Helicobacter Pylori Naive Subjects

Germany
Imvax

Recruiting

A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

Glioblastoma

United States
GemVax & Kael

Recruiting

Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

Progressive Supranuclear Palsy

Korea, Republic of
GemVax & Kael

Active, not recruiting

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

Mild to Moderate Alzheimer's Disease

Spain, United States, Netherlands, Poland
GemVax & Kael

Withdrawn

GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)

Moderate Alzheimer's Disease
GemVax & Kael

Completed

Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hyperplasia (BPH)

Korea, Republic of
GemVax & Kael

Completed

Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients

Alzheimer Disease

Korea, Republic of
GemVax & Kael

Recruiting

GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

Korea, Republic of
GemVax & Kael

Completed

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH

Benign Prostatic Hyperplasia (BPH)

Korea, Republic of
Impax Laboratories, LLC

Completed

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

Parkinson's Disease

United States, Canada, France, Germany, Poland, Romania, Spain, Ukraine
Impax Laboratories, LLC

Completed

An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease

Parkinson's Disease

United States, Canada, Estonia, Latvia, Lithuania, Romania, Ukraine, Germany, Poland, Spain
Impax Laboratories, LLC

Completed

A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

Parkinson's Disease

United States
Impax Laboratories, LLC

Completed

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease (APEX-PD)

Parkinson's Disease

United States, Canada, Estonia, Latvia, Lithuania, Romania, Ukraine
PrimeVax Immuno-Oncology Inc.

Not yet recruiting

Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma

Metastatic Melanoma
Impax Laboratories, LLC

Completed

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

Cardiac Repolarization in Healthy Subjects

United States
Impax Laboratories, LLC

Completed

A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

Advanced Parkinson's Disease

United States
Impax Laboratories, LLC

Completed

A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

Parkinson's Disease

United States
Impax Laboratories, LLC

Completed

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

United States
Impax Laboratories, LLC

Completed

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

United States
Impax Laboratories, LLC

Completed

Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations

Parkinson Disease

United States, Czechia, France, Germany, Italy, Poland, Spain, United Kingdom
Impax Laboratories, LLC

Completed

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

Parkinson's Disease (Disorder)

United States, Czechia, France, Italy, Spain, Germany, Poland, United Kingdom
Impax Laboratories, LLC

Completed

A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States
Impax Laboratories, LLC

Completed

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Estonia, Latvia, Ukraine
Impax Laboratories, LLC

Completed

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

Parkinson's Disease

Germany, United States, France, Italy
Impax Laboratories, LLC

Completed

Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease

Parkinson's Disease

United States
Impax Laboratories, LLC

Completed

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

Restless Legs Syndrome

United States
Impax Laboratories, LLC
AstraZeneca

Completed

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

Migraine

United States
LiteVax BV
University Hospital, Ghent

Completed

Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin (TETRALITE-I)

Influenza

Belgium
MimiVax, LLC
Translational Drug Development; Merit

Active, not recruiting

SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (SURVIVE)

Newly Diagnosed Glioblastoma

United States
Kael-GemVax Co., Ltd.
Quintiles, Inc.

Unknown

Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer (LucaVax)

Inoperable Stage III Non-small Cell Lung Cancer
THEVAX Genetics Vaccine
Clinical Research Management, Inc.

Unknown

Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

Human Papillomavirus | High-Grade Squamous Intraepithelial Lesions

United States
Padagis LLC
Impax Laboratories, LLC

Completed

Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy

Atrophy

United States
Lytix Biopharma AS
Kael-GemVax Co., Ltd.

Completed

A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma

Carcinoma

Norway
LiteVax BV
University Hospital, Ghent; HarmonyCR, Melle, Belgium

Recruiting

Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine (TETRALITE-Ib)

Vaccination Reaction

Belgium
Kael-GemVax Co., Ltd.
National Cancer Institute (NCI)

Unknown

Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer

Prostate Cancer

United States
metaX Institut fuer Diatetik GmbH
Birmingham Children's Hospital

Completed

Acceptability and Tolerance of a Ready-to-use Protein Substitute in Tablet Form for the Dietary Management of Phenylketonuria

Phenylketonurias | Hyperphenylalaninaemia | Tetrahydrobiopterin Deficiency

United Kingdom
PrimeVax Immuno-Oncology Inc.
Walter Reed Army Institute of Research (WRAIR)

Not yet recruiting

Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma

Advanced Melanoma
PrimeVax Immuno-Oncology Inc.
Walter Reed Army Institute of Research (WRAIR)

Not yet recruiting

Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma

Advanced Melanoma
Impax Laboratories, LLC
Michael J. Fox Foundation for Parkinson's Research

Completed

Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

Parkinson's Disease

United States
metaX Institut fuer Diatetik GmbH
Great Ormond Street Hospital for Children NHS Foundation Trust; Birmingham...

Not yet recruiting

Acceptability/Tolerance of Protein Substitutes in Tablet Form for the Dietary Management of Rare Aminoacidopathies (ZeroMinisMR)

Alkaptonuria | Homocystine; Metabolic Disorder | Tyrosinemia, Type I | Tyrosinemia, Type II | Tyrosinemia, Type III | MSUD (Maple Syrup Urine Disease)
ANRS, Emerging Infectious Diseases
IMEA Leon M'Ba Foundation; Unit 1136 INSERM, Faculty of medecine, University...

Unknown

Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients (QUATUOR)

HIV Infections

France
University of Pennsylvania
National Institute of Drug Abuse; The Wistar Institute; Ho Chi Minh City CDC; Institute...

Recruiting

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1 (AMOHI-1)

Inflammation | Opioid-use Disorder | HIV-1-infection | Immune Activation | Buprenorphine | Methadone | Naltrexone | Antiretroviral Treatment

United States, Vietnam
ANRS, Emerging Infectious Diseases
Institut Pasteur; Hôpital Necker-Enfants Malades; Hospital Avicenne; CHU Kamenge... and other collaborators

Unknown

Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa (Flucocrypto)

HIV | Cryptococcal Meningitis

Burundi, Côte D'Ivoire

Clinical Trials Sponsored by ImevaX

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations